Oryzon Raises €18 Million through a Private Placement with US and European Investors

BARCELONA, SPAIN and CAMBRIDGE MA.

Oryzon Genomics, S.A. (Madrid Stock Exchange: ORY, “Oryzon” or the “Company”), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, today announced the successful completion of a capital increase of 5,693,565 new common shares, with gross proceeds of approximately €18.2 million. This represents the maximum capital increase the company could undertake under the current approved resolutions of its General Assembly. The shares were sold at a price of €3.20 per share.

 

Click here to see the full Press Release